Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled dose-escalation study of pynegabine tablets as add-on therapy in focal epilepsy
CTR20241138Phase 2Completed
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pynegabine in Focal Onset Epilepsy, sponsored by Shanghai Institute of Materia Medica. Started Aug 2024; status: completed.
02
Drugs
pynegabine
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on CTR20241138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241138.